Given that anti CTLA-4 has previously been shown to be highly effective against AB12 tumors we selected using this agent to test whether AB12 tumor respond to immunotherapy in a tumor growth phase dependent manner (8, 20). The gene discussed is CTLA4; the disease is neoplasm.